Market Access Impact: Renal Cell Carcinoma (US)

Market Access Impact: Renal Cell Carcinoma (US)

  • May 2016 •
  • Report ID: 3866842 •
  • Format: PDF



Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them?
We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists can’t prescribe freely. The result: 6 of those brands actually saw a net gain.
Is your brand one of them, or one of the 3 that are losing out?
You’ll learn how market barriers affect share for 9 major treatments from Bayer/Amgen, BMS, Genentech, Pfizer, and Prometheus.
Plus you’ll see which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.





Get Answers to Key Questions about RCC Drug Brands


Afinitor (everolimus; Novartis): Does Afinitor lose more share to Avastin or Sutent?
Avastin (bevacizumab; Genentech): Are doctors who don’t prescribe either brand more likely to consider Avastin or Opdivo?
Inlyta (axitinib; Pfizer): Which two barriers contribute equally to Inlyta’s small net share loss?
Nexavar (sorafenib; Bayer/Amgen): Does Nexavar gain more share when other brands are too expensive or when they’re not reimbursable?
Opdivo (nivolumab; BMS): Opdivo and Sutent are prescribed equally. Which one has the clear market share advantage?
Proleukin (aldesleukin; Prometheus): Which three barriers do more doctors experience with Proleukin than any other brand?
Sutent (sunitinib; Pfizer): Which two brands would threaten Sutent if market barriers were eliminated?
Torisel (temsirolimus; Pfizer): Torisel sees a net gain against all but three brands. Which three?
Votrient (pazopanib; Novartis): Only two market barriers contribute to Votrient’s net share gain. What are they?

Top Takeaways


Most brands benefit from barriers: Six of the nine surveyed brands saw a net share gain due to barriers. Only three saw a net loss.
Eliminating barriers would shake up the market: Especially the top of the market, where one middle-ranked brand would move into the top 3, pushing a leading brand out.
Barrier effect is brand-specific: Each barrier tends to affect one or two brands far more than the others.
All brands are heavily prescribed: Although a majority of doctors prescribe all but one of the surveyed brands, two brands are more prescribed than any of the others.
Clear market leaders: Two brands—one of them among the most prescribed—have a clear market share lead.
Brand perception is good: With a few exceptions, most doctors are willing to consider prescribing the brands they don’t currently prescribe.
Cost barriers have the greatest impact: barriers related to pricing and formulary availability (which is often related) affect more prescriptions than any others.
Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 7 of the surveyed brands, and see the third biggest net share gain.

Exploring Market Access Issues
Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You’ll learn:

How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 100 medical oncologists in the US, chosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.